The Experts below are selected from a list of 8364 Experts worldwide ranked by ideXlab platform

Michael I Maggio - One of the best experts on this subject based on the ideXlab platform.

Robert M Kay - One of the best experts on this subject based on the ideXlab platform.

  • clinical behavior and a contemporary management algorithm for prepubertal Testis Tumors a summary of the prepubertal Testis Tumor registry
    The Journal of Urology, 2002
    Co-Authors: Jonathan H Ross, Lisa Rybicki, Robert M Kay
    Abstract:

    ABSTRACTPurpose: The Prepubertal Testis Tumor Registry was established by the Urologic Section of the American Academy of Pediatrics in 1980 to record data on a large number of prepubertal Testis Tumors regarding presentation, treatment and outcome to define appropriate management better. We reviewed the registry data in the context of other modern studies to elucidate the appropriate management of these rare Tumors.Materials and Methods: Relevant data in the prepubertal Testis Tumor registry were tabulated and analyzed.Results: There were 395 prepubertal patients who had a primary Testis Tumor. Generally benign Tumors accounted for 38% of cases. A significant proportion of Tumors were benign regardless of patient age. α-Fetoprotein levels for patients with benign and malignant Tumors overlapped in children younger than 6 months. Of the patients with yolk sac Tumor 80% presented with stage 1 disease and overall survival was excellent. There were no metastases or deaths among the patients with teratoma. Of...

  • patterns of metastatic spread in prepubertal yolk sac Tumor of the Testis
    The Journal of Urology, 1995
    Co-Authors: Richard W Grady, Jonathan H Ross, Robert M Kay
    Abstract:

    AbstractOf the 212 patients with yolk sac Tumors of the Testis registered in the prepubertal Testis Tumor registry of the American Academy of Pediatrics, Section on Urology, we report on 33 who presented with metastatic disease. Metastases occurred to the retroperitoneum alone in 9 cases, sites consistent with hematogenous spread of disease alone in 13, sites consistent with lymphatic and hematogenous spread in 6, and sites not clearly documented in the registry in 5. These findings, which show a hematogenous predilection in the spread of metastases, suggest that retroperitoneal lymph node dissection has no routine role in the treatment of the child who presents with yolk sac Tumor of the Testis.

Noah S Schenkman - One of the best experts on this subject based on the ideXlab platform.

Beate Koberle - One of the best experts on this subject based on the ideXlab platform.

  • elevation of xpa protein level in Testis Tumor cells without increasing resistance to cisplatin or uv radiation
    Molecular Carcinogenesis, 2008
    Co-Authors: Beate Koberle, Vera Roginskaya, Karen S Zima, J R W Masters, Richard D Wood
    Abstract:

    Most testicular germ cell Tumors are curable using cisplatin-based chemotherapy, and cell lines from these Tumors are unusually sensitive to cisplatin and other DNA-damaging agents. It has been suggested that this might be caused by a lower-than normal nucleotide excision repair (NER) activity. Previous studies found that cell lines from testicular germ cell Tumors have on average about one-third the level of the NER protein XPA in comparison to cell lines from other Tumors. We asked whether over-expression of XPA protein would alleviate the cellular sensitivity and increase the DNA repair capacity of a Testis Tumor cell line. Increasing XPA levels in 833K cells by 10-fold did not increase resistance to UV irradiation. XPA was localized to the cell nucleus in all cell lines, before and after exposure to UV-radiation. 833K cells were proficient in removing UV radiation-induced photoproducts from the genome and increased XPA did not enhance the rate of removal. Further, over-expressing functional XPA protein did not correlate with increased resistance of 833K Testis Tumor cells to cisplatin. Thus, although the amount of XPA in this Testis Tumor cell line is lower than normal, it is sufficient for NER in vivo. The relative sensitivity of Testis Tumor cells to cisplatin, UV radiation, and other DNA damaging agents is likely related not to NER capacity, but to other factors such as the integrity of the p53 pathway in these cells.

  • reduced levels of xpa ercc1 and xpf dna repair proteins in Testis Tumor cell lines
    International Journal of Cancer, 2004
    Co-Authors: Carey Welsh, J R W Masters, Richard D Wood, Roger Day, Claire J Mcgurk, Beate Koberle
    Abstract:

    Over 80% of patients with advanced metastatic Testis Tumors can be cured using cisplatin-based combination chemotherapy. This is unusual as metastatic cancer in adults is usually incurable. Cell lines derived from Testis Tumors retain sensitivity to cisplatin in vitro. We previously investigated 2 Testis Tumor cell lines with a low capacity to remove cisplatin-induced DNA damage and found that they had low levels of the DNA nucleotide excision repair proteins XPA, ERCC1 and XPF. To determine whether low levels of XPA, ERCC1 and XPF proteins are characteristic of Testis Tumor cell lines, we investigated 35 cell lines derived from cancers to determine whether groups of cell lines from diverse tissue origins differ from one another in constitutive levels of these NER proteins. Quantitative immunoblotting was used to compare groups of cell lines representing prostate, bladder, breast, lung, cervical, ovarian and Testis cancers. Only the 6 Testis Tumor cell lines showed significantly lower mean levels of XPA (p = 0.001), XPF (p = 0.001) and ERCC1 (p = 0.004) proteins from the other groups. Our results encourage further investigation of the possibility that low levels of these nucleotide excision repair proteins could be related to the favorable response of Testis Tumors to cisplatin-based chemotherapy.

Jonathan H Ross - One of the best experts on this subject based on the ideXlab platform.

  • clinical behavior and a contemporary management algorithm for prepubertal Testis Tumors a summary of the prepubertal Testis Tumor registry
    The Journal of Urology, 2002
    Co-Authors: Jonathan H Ross, Lisa Rybicki, Robert M Kay
    Abstract:

    ABSTRACTPurpose: The Prepubertal Testis Tumor Registry was established by the Urologic Section of the American Academy of Pediatrics in 1980 to record data on a large number of prepubertal Testis Tumors regarding presentation, treatment and outcome to define appropriate management better. We reviewed the registry data in the context of other modern studies to elucidate the appropriate management of these rare Tumors.Materials and Methods: Relevant data in the prepubertal Testis Tumor registry were tabulated and analyzed.Results: There were 395 prepubertal patients who had a primary Testis Tumor. Generally benign Tumors accounted for 38% of cases. A significant proportion of Tumors were benign regardless of patient age. α-Fetoprotein levels for patients with benign and malignant Tumors overlapped in children younger than 6 months. Of the patients with yolk sac Tumor 80% presented with stage 1 disease and overall survival was excellent. There were no metastases or deaths among the patients with teratoma. Of...

  • patterns of metastatic spread in prepubertal yolk sac Tumor of the Testis
    The Journal of Urology, 1995
    Co-Authors: Richard W Grady, Jonathan H Ross, Robert M Kay
    Abstract:

    AbstractOf the 212 patients with yolk sac Tumors of the Testis registered in the prepubertal Testis Tumor registry of the American Academy of Pediatrics, Section on Urology, we report on 33 who presented with metastatic disease. Metastases occurred to the retroperitoneum alone in 9 cases, sites consistent with hematogenous spread of disease alone in 13, sites consistent with lymphatic and hematogenous spread in 6, and sites not clearly documented in the registry in 5. These findings, which show a hematogenous predilection in the spread of metastases, suggest that retroperitoneal lymph node dissection has no routine role in the treatment of the child who presents with yolk sac Tumor of the Testis.